Zai Lab Q4 Revenue Up 17% to $127.6M, zoci Delivers 80% Brain ORR
Zai Lab’s Q4 revenue rose 17% year-over-year to $127.6 million with operating loss narrowing 19% to $229.4 million and $790 million cash on hand. Its DLL3-targeting ADC zoci showed an 80% intracranial response in 10 untreated brain-metastasis patients and entered a 480-patient Phase III aiming for 2027 accelerated approval.
1. Q4 Financial Performance
In Q4, Zai Lab reported 17% year-over-year revenue growth to $127.6 million, full-year revenue of $460 million, and narrowed its operating loss by 19% to $229.4 million. The company closed the quarter with $790 million in cash, advancing toward cash-flow breakeven.
2. zoci Phase III Progress and Brain Metastases Data
Zai Lab’s DLL3-targeting ADC zoci entered a global registrational Phase III trial in second- and third-line small cell lung cancer with approximately 480 patients and a control arm reflecting real-world treatments. Early intracranial activity showed an 80% objective response rate in 10 untreated brain-metastasis patients, supporting a planned 2027 accelerated approval submission.
3. Global Pipeline Expansion
Beyond zoci, Zai Lab advanced U.S. IND clearance for ZL-6201, progressed IND-enabling work for ZL-1222 and ZL-1311, and initiated enrollment for ZL-1503 with first-in-human data expected in 2026. Additional late-stage readouts include an interim analysis for povetacicept in IgA nephropathy and top-line results for REVEAL studies in thyroid eye disease.